[Effects of valsartan and captopril on expressions and activities of tissue factor and tissue factor pathway inhibitor].
OBJECTIVE
To investigate the effects of ox-LDL, ACEI and ARB on expressions and activities of TF and TFPI in VSMC.


METHODS
(1) Rabbit VSMC was cultured by explant-attached method in vitro. (2) The effects of ox-LDL and valsartan on TF and TFPI expressions were analyzed by immunohistochemistry and immunofluorescence. Laser scanning confocal microscopy were applied to analyze the effects of ox-LDL and valsartan on TF expression. The effects of ox-LDL, valsartan and captopril on TF and TFPI antigen expressions were analyzed by ELISA. Chromogenic substrate method was used to determine the effects of ox-LDL, valsartan and captopril on TF activity. The effects of ox-LDL and valsartan on TF mRNA expression were analyzed by RT-PCR.


RESULTS
(1) ox-LDL could upregulate TF antigen, activity and TF expression at mRNA level and downregulate TFPI antigen. (2) Valsartan and captopril could reduce TF antigen and activity in VSMC treated by ox-LDL, and valsartan reduce it in a dose-dependent manner. Valsartan could also attenuate TF expression at mRNA level in VSMC treated by ox-LDL. (3) Using ELISA, valsartan and captopril could also enhance TFPI antigen in VSMC treated by ox-LDL.


CONCLUSIONS
Our study showed upregulated TF and downregulated TFPI expression and activity by ox-LDL and these effects could be reversed by ACEI and ARB indicating a new insight on the antiatherosclerotic effects of ACEI and ARB.
Li
Na
N
Department of Cardiology, China-Japan Friendship Hospital, and Peking Union Medical College, Beijing 100029, China.
Zhu
Wen-ling
WL
Chen
Lian-feng
LF
Ke
Yuan-nan
YN
D000818:Animals; D002216:Captopril / Q000494:pharmacology*; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism; D008297:Male; D006180:Proton-Translocating ATPases / Q000096:biosynthesis* / Q000235:genetics; D012333:RNA, Messenger / Q000096:biosynthesis; D011817:Rabbits; D013777:Tetrazoles / Q000494:pharmacology*; D013925:Thromboplastin / Q000096:biosynthesis* / Q000235:genetics; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan
D012333:RNA, Messenger; D013777:Tetrazoles; D000068756:Valsartan; D013925:Thromboplastin; D002216:Captopril; D006180:Proton-Translocating ATPases; D014633:Valine